已收录 268921 条政策
 政策提纲
  • 暂无提纲
Development and Validation of RP-HPLC method for SimultaneousDetermination of Hydrochlorthiazide and Eprosartan in Bulk andPharmaceutical Dosage Form
[摘要] An accurate, highly sensitive, precise and reproducible isocratic RP-HPLC method was developed and subsequent validated for the simultaneous analysis of Hydrochlorthiazide and Eprosartan in bulk and tablet dosage forms. Method development was carried out on Agilent Eclipse XBD-C18 (5μm, 150mm × 4.6mm I.D.) column. The mobile phase was a mixture of buffer (20mM KH2PO4) and methanol in the ratio of 80:20 v/v. The flow rate was set at 1.0 ml/min and UV detection at 225nm. The retention time of Hydrochlorthiazide and Eprosartan were found to be 3.34 min and 4.75 min respectively. Validation parameters such as linearity, accuracy, precision, and robustness, limit of detection (LOD) and limit of quantification (LOQ) were evaluated for the method according to the International Conference on Harmonization (ICH) Q2 R1 guidelines. In the linearity study, the regression equations Hydrochlorthiazide and Eprosartan were found to be y=0.0123x + 0.0019 and y=0.0034x - 0.0163. Correlation coefficient was 0.9984 and 0.9989 for Hydrochlorthiazide and Eprosartan respectively. The proposed method was successfully applied for the quantification of bulk and active pharmaceutical present in tablet dosage form.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 药理学
[关键词]  [时效性] 
   浏览次数:3      统一登录查看全文      激活码登录查看全文